'We have failed to fail': Mer­ck gam­bles $250M cash on a next-gen ap­proach to mR­NA — af­ter punt­ing its big al­liance with Mod­er­na

Mer­ck went in deep on its col­lab­o­ra­tion with Mod­er­na on new mR­NA pro­grams, and dropped them all over time, in­clud­ing their RSV part­ner­ship. But af­ter writ­ing off what turned out as one of the most suc­cess­ful in­fec­tious dis­ease play­ers in the busi­ness, Mer­ck is com­ing in this morn­ing with a new pre­clin­i­cal al­liance — this time em­brac­ing a biotech that hopes to even­tu­al­ly out­do the fa­mous­ly suc­cess­ful mR­NA in a new run at vac­cines and ther­a­peu­tics.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER